Development of 3DMPUS as a Decision Support Tool for Patients With Liver Tumors Undergoing Therapy (3DMPUS)
Liver Cancer, Adult

About this trial
This is an interventional diagnostic trial for Liver Cancer, Adult focused on measuring Diagnostic Study
Eligibility Criteria
Inclusion Criteria: The participant is about to undergo a new course of therapy for primary or metastatic liver cancer. The participant is age > 18 years. Participant has at least one target lesion (≥1cm and <14cm) The participant is willing to comply with protocol requirements. The participant has the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Participant has documented anaphylactic or other severe reactions to any ultrasound or CT contrast media. Participant has documented severe Hypersensitivity to macrogol/ polyethylene glycol (PEG). Participant has documented the presence of a cardiac shunt or pulmonary hypertension (pulmonary artery pressure >90 mmHg). Participant has documented renal insufficiency with a creatinine level of >1.5mg/dl. Participant has documented uncontrolled systemic hypertension. Participant has documented concomitant diseases like acute endocarditis, prosthetic valve, hyperactive coagulation states and/ or recent thromboembolism, and sepsis Participant is pregnant (positive urine or serum beta-hCG) or lactating.
Sites / Locations
- Stanford University, School of Medicine
- Thomas Jefferson Hospital
Arms of the Study
Arm 1
Experimental
3-dimensional multi-parametric ultrasound imaging (3D-MPUS)
Patients receive sulfur hexafluoride IV and undergo 3D-MPUS imaging over 20 minutes.